Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of “Moderate Buy” from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $25.4444.

ARCT has been the topic of several recent research reports. Piper Sandler cut their target price on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. B. Riley Financial initiated coverage on Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 target price on the stock. Citigroup cut their target price on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Finally, Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st.

Arcturus Therapeutics Stock Down 1.5%

Shares of ARCT stock opened at $7.65 on Wednesday. The firm has a market capitalization of $217.41 million, a P/E ratio of -2.72 and a beta of 2.36. Arcturus Therapeutics has a twelve month low of $5.85 and a twelve month high of $24.17. The stock’s fifty day simple moving average is $7.97 and its 200 day simple moving average is $7.41.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.08. The business had revenue of $2.06 million for the quarter, compared to analyst estimates of $6.30 million. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%. As a group, equities research analysts expect that Arcturus Therapeutics will post -4.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $128,000. Millennium Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $4,892,000. Goldman Sachs Group Inc. lifted its stake in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after purchasing an additional 42,636 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $701,000. Finally, Strs Ohio acquired a new position in shares of Arcturus Therapeutics in the 1st quarter valued at about $89,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.